Drug details

Rezvoglar (insulin glargine-aglr injection)

type of Antidiabetics, Long-Acting Insulins

Rezvoglar (insulin glargine-aglr) is a long-acting human insulin analog indicated to improve glycemic control in adults and pediatric patients with type 1 diabetes mellitus and in adults with type 2 diabetes mellitus.

The drug is often used to treat Type 2 diabetes .

This drug may have the following side effects:

• hives, 
• difficulty breathing, 
• swelling of your face, lips, tongue, or throat, 
• Heart failure
• severe dizziness, 
• low blood sugar, 
• low potassium levels, and

The following drugs are related to Rezvoglar, either as a replacement or used together:

• Basaglar (basaglar insulin glargine subcutaneous injection)
• Lantidra (donislecel-jujn allogeneic pancreatic islet cellular)
• Lantus (insulin glargine [rdna origin] injection)
• Toujeo (insulin glargine injection for subcutaneous use)
• Tzield (teplizumab-mzwv injection, for intravenous use)